Northw.Bio Regs Share Discussion Threads

[ltinvestor] 11/7/2007 07:52

Down over $2 in US last night.

[andrbea] 11/7/2007 07:37

medical tourism:


Swiss approve cancer vaccine made by Northwest Biotherapeutics
BLOOMBERG NEWS

Northwest Biotherapeutics Inc., a Bothell-based biotechnology company, won Swiss approval for its brain-cancer treatment, the first vaccine to harness a patient's immune system to fight the disease.

The product will be produced in the U.S., and made available to patients at treatment centers in Switzerland, Northwest Biotherapeutics said Monday in a prepared statement.

The company is working to win approval in the U.S. and Europe to gain access to the $35 billion market for cancer treatments. In clinical trials, patients treated with DCVax-Brain survived twice as long as those who didn't receive the vaccine, without major side effects, the company said.

"This is an unprecedented product," said Navid Malik, an analyst at Collins Stewart. "The whole field has opened up with this vaccine."

Though the vaccine has only been approved in Switzerland, patients from all over Europe are likely to travel for treatment, Malik said.

The product combines the patient's immune cells with so-called cancer biomarkers from the tumor and injects the solution into the patient, the company said in the statement. DCVax-Brain allows the immune system to fight the disease without side effects. Studies found the medicine delays recurrence of the tumor by 18.1 months for new patients, Northwest said.

Malik upgraded his 2009 sales forecasts to $36 million from $15 million and net income to $11.5 million from $3.3 million.

He has a "strong buy" rating on the shares.

"I believe this will become the standard of care globally," Malik said.

According to the U.S. National Cancer Institute, there are 19,000 new cases of primary brain cancer diagnosed each year. The five-year survival rate is around 30 percent.

"Switzerland is an attractive place to begin commercialization, due to its highly respected regulatory oversight," Northwest Chief Executive Alton Boynton said in the statement.

[andrbea] 11/7/2007 07:36

Shares soar in brain cancer vaccine firm
By Karen Attwood
Published: 11 July 2007
An experimental treatment for brain cancer developed by the AIM-listed Northwest Biotherapeutics has won regulatory approval, sending shares in the company up 82 per cent to 255p.

[3matt3] 10/7/2007 20:56

NWBO is trading now at 4.97

[andrbea] 10/7/2007 17:22

trade of 133158 units at 17.29h
chunky size that..

bubsy2:



andrbea - 10 Jul'07 - 16:08 - 67 of 70 edit


mkt cap of Dendreon (USD)

Market Cap 642.16 m

mkt cap of nwbo

32 m

[bubsy2] 10/7/2007 16:36

what is the mkt cap on this confussed.....

[andrbea] 10/7/2007 16:26

with a mkt cap 20 times bigger, why doesn't DNDN just buy up nwbo?

DNDN having difficulty getting FDA approval for their cancer vaccines

[markralph] 10/7/2007 16:10

this is a Reg S share - what restrictions (if any) are there for UK clients?!?!?

TIA.

all 3 listings looks worthy today.

[andrbea] 10/7/2007 16:08

mkt cap of Dendreon

Market Cap 642.16 m

mkt cap of nwbo

32 m

[andrbea] 10/7/2007 16:05

While there has been tremendous hype and controversy surrounding companies developing cancer vaccines, including Dendreon (DNDN) and Cell Genesys (CEGE), a tiny Swiss biotech company took center stage on Monday. Northwest BioTherapeutics (NWBO.OB) announced that the Swiss Institute of Public Health had cleared its dendretic-cell vaccine, DCVax®-Brain, for commercial launch for treatment of brain cancer

So, it is possible that the company will produce the vaccine in the U.S., and end up selling it to Americans in Switzerland, at much higher prices! The company is currently conducting Phase II trials in both the U.S. and EU, but expects final results by end of 2008.

The company is also cleared to investigate its DCVax® Technology platform in various other cancers, including a phase III trial for prostate cancer. This should make Dendreon investors a little nervous. The company's DCVax® Technology has tremendous advantages over competing cancer vaccine platforms.


/..


Even following Monday's jump in share price, the company still has a tiny market cap of only $32 million. If you thought Dendreon shares are wild, think again!

[james 2] 10/7/2007 15:54

Bloody hell GS you must have big boots to fill with that credit limit, mind you smaller pockets than me if you don't have any room for the wallet :o)

[andrbea] 10/7/2007 15:40

Paul Murphy and Neil Hume will also be looking at Northwest Biotherapeutics, a company which believes it has developed a vaccine for brain cancer.

So tune in to Markets Live at 11am. You might live longer

[andrbea] 10/7/2007 15:40

We'll do more on Northwest Biotherapeutics, which claims to have found a vaccine for brain cancer. It shares, listed on Aim, rose 34 per cent yesterday and are up another 57 per cent. As they say on FT Alphaville, this is either a company with a wonder drug and is heading for the moon, or it isn't.

[andrbea] 10/7/2007 15:39

In reaction, Collins Stewart reiterated its 'buy' recommendation and 300 pence target price on the stock and upped its 2008 forecasts for sales of 15 mln usd and a net profit of 3.3 mln usd

[andrbea] 10/7/2007 15:33

The 2nd product line (prostrate) looks promising too


Clinical trial data to date in hormone independent prostate cancer patients
have shown striking results similar to the results in brain cancer
/...


The Company has two broad platform technologies:
(1.) dendritic cell-based therapeutic vaccines and (2.) antibody drugs.
The Company's lead product candidates are:
1. DCVax(R)-Brain, a personalized dendritic cell vaccine for treatment of
Glioblastoma multiforme, which has reached the market commercially in
Switzerland and, in parallel, has been under way since December, 2006,
in a Phase II pivotal clinical in the US which is expected to finish
around the end of 2008; and

2. DCVax(R)-Prostate, a personalized dendritic cell vaccine for treatment
of hormone independent non-metastatic prostate cancer, which has been
cleared by the FDA to enter a Phase III pivotal clinical trial in the
US.

[andrbea] 10/7/2007 15:26

-19% (States)

[simonparker5] 10/7/2007 14:58

OK I am confused now. Trading at over $6 dollars yet we go down to £2.1. NO logic at all.

[gimme sunshine] 10/7/2007 14:39

makes sense really. still I'm sure once they sell they will pick up the phone and buy the aim one instead. still a lot more to go. imho

[callumross] 10/7/2007 14:36

now $5.90!

[callumross] 10/7/2007 14:33

now crashing in US - $6.50 now!

[callumross] 10/7/2007 14:32

oops -down we go in the US!

[andrbea] 10/7/2007 14:25

The company is working to win approval in the U.S. and Europe to gain access to the $35 billion market for cancer treatments. In clinical trials, patients treated with DCVax-Brain survived twice as long as those who didn't receive the vaccine, without major side effects, the company said.

"This is an unprecedented product," said Navid Malik, an analyst at Collins Stewart. "The whole field has opened up with this vaccine."

Though the vaccine has only been approved in Switzerland, patients from all over Europe are likely to travel for treatment, Malik said.

The product combines the patient's immune cells with so-called cancer biomarkers from the tumor and injects the solution into the patient, the company said in the statement. DCVax-Brain allows the immune system to fight the disease without side effects. Studies found the medicine delays recurrence of the tumor by 18.1 months for new patients, Northwest said.

Malik upgraded his 2009 sales forecasts to $36 million from $15 million and net income to $11.5 million from $3.3 million.

He has a "strong buy" rating on the shares.

"I believe this will become the standard of care globally," Malik said.

According to the U.S. National Cancer Institute, there are 19,000 new cases of primary brain cancer diagnosed each year. The five-year survival rate is around 30 percent.